2,004 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Bought by Guardian Wealth Advisors LLC NC

Guardian Wealth Advisors LLC NC bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the fourth quarter, HoldingsChannel reports. The firm bought 2,004 shares of the biotechnology company’s stock, valued at approximately $244,000.

Other large investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its position in Sarepta Therapeutics by 2.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company’s stock valued at $75,842,000 after buying an additional 12,000 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in Sarepta Therapeutics in the 4th quarter valued at $3,829,000. Allspring Global Investments Holdings LLC raised its position in Sarepta Therapeutics by 16,717.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company’s stock valued at $10,602,000 after buying an additional 84,926 shares during the last quarter. Van ECK Associates Corp raised its position in Sarepta Therapeutics by 24.4% in the 4th quarter. Van ECK Associates Corp now owns 84,834 shares of the biotechnology company’s stock valued at $10,315,000 after buying an additional 16,658 shares during the last quarter. Finally, Sivik Global Healthcare LLC purchased a new stake in Sarepta Therapeutics in the 4th quarter valued at $1,216,000. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Down 0.7%

SRPT stock opened at $36.27 on Monday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $3.56 billion, a PE ratio of 29.02 and a beta of 0.85. Sarepta Therapeutics, Inc. has a twelve month low of $35.46 and a twelve month high of $173.25. The stock has a 50-day simple moving average of $66.84 and a two-hundred day simple moving average of $100.44.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The company had revenue of $744.86 million for the quarter, compared to analysts’ expectations of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The firm’s quarterly revenue was up 80.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.73 EPS. On average, equities analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on SRPT shares. Evercore ISI lowered Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 price target for the company. in a research report on Thursday. HC Wainwright decreased their target price on Sarepta Therapeutics from $75.00 to $40.00 and set a “neutral” rating for the company in a research report on Wednesday, May 7th. Royal Bank of Canada decreased their target price on Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating for the company in a research report on Wednesday, May 7th. Scotiabank decreased their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research report on Thursday, March 20th. Finally, Morgan Stanley decreased their target price on Sarepta Therapeutics from $182.00 to $113.00 and set an “overweight” rating for the company in a research report on Wednesday, May 7th. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $131.22.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares of the company’s stock, valued at $2,771,187.68. The trade was a 8.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.